Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai Patents (Class 514/183)
  • Patent number: 8618085
    Abstract: Formulations of desoxyepothilones are stable before and after dilution into aqueous media.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: December 31, 2013
    Assignee: Koasn Biosciences Incorporated
    Inventors: Peter J. Licari, Ziyang Zhong, Indu Isaacs, John G. Augustine
  • Patent number: 8618087
    Abstract: In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: December 31, 2013
    Assignee: Marinus Pharmaceuticals
    Inventors: Kenneth Shaw, Mingbao Zhang
  • Patent number: 8617906
    Abstract: The identification of triptolide target molecules is described. Also described are methods of screening triptolide-related compounds for binding to these molecules, including screening for enhanced and/or selective binding, and expression analysis of the target molecules in normal and in diseased tissue.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: December 31, 2013
    Assignee: Pharmagenesis, Inc.
    Inventors: John M. Fidler, John H. Musser
  • Patent number: 8618086
    Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: December 31, 2013
    Assignee: Duke University
    Inventors: Mitchell Anthony deLong, John McMillan McIver, Robert Scott Youngquist
  • Patent number: 8614204
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: December 24, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Patent number: 8614205
    Abstract: The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds.
    Type: Grant
    Filed: June 2, 2012
    Date of Patent: December 24, 2013
    Inventors: Richard D Wood, William Welsh
  • Patent number: 8614168
    Abstract: The invention relates to the use of at least one compound, selected from the group consisting of tebuconazole, epoxiconazole, metconazole, cyproconazole, prothioconazole and any mixtures thereof, for increasing the resistance of plants to abiotic stress factors.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: December 24, 2013
    Assignee: Monheim
    Inventors: Jan Dittgen, Isolde Häuser-Hahn, Heinz Kehne, Stefan Lehr, Jörg Tiebes, Marco Busch
  • Publication number: 20130336962
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, R3, R4, M1, M2, X, L1, L2, J1, J2, a1, a2, b1 and b2 are as defined herein, and wherein at least one of M2 or L2 is a moiety comprising an aziridine, acrylamide or sulfonate functional group, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: April 16, 2013
    Publication date: December 19, 2013
    Applicants: The University of Biritish Columbia, British Columbia Cancer Agency Branch
    Inventors: British Columbia Cancer Agency Branch, The University of British Columbia
  • Patent number: 8609646
    Abstract: The present invention relates to methods and compounds for decreasing the expression of hepcidin, a protein associated with regulation of iron metabolism.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: December 17, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Patent number: 8604078
    Abstract: The present invention relates to a solid fosfomycin pharmaceutical composition stable in front the coloration, suitable for diabetics and not entailing gastrointestinal problems. The pharmaceutical composition of this invention comprises fosfomycin trometamol, glycine, and optionally other excipients as sucralose, silice dioxide, polyvinylpyrrolidone and flavor; and is substantially free from sugars and sugar alcohols as sucrose, fructose, glucose, xylitol, mannitol, sorbitol or mixtures thereof.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: December 10, 2013
    Inventor: Carlos Picornell Darder
  • Patent number: 8604015
    Abstract: Compounds according to formula (I) are effective for the treatment of broncho-obstructive and inflammatory diseases.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: December 10, 2013
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Gabriele Amari, Mauro Riccaboni, Daniele De Zani
  • Patent number: 8604014
    Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: December 10, 2013
    Assignees: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Marcia Belvin, Lori Friedman, Klaus Hoeflich, Deepak Sampath, Ulka Vijapurkar, Jeffrey Wallin, Leisa Johnson, Mallika Singh, Sonal Patel
  • Patent number: 8604012
    Abstract: The present invention relates to methods and compounds for increasing serum iron in a subject.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: December 10, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Patent number: 8604013
    Abstract: The present invention relates to methods for treating anemia in a subject having a low percent transferrin saturation by administering to the subject an effective amount of a compound that inhibits hypoxia-inducible factor prolyl hydroxylase activity.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: December 10, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Publication number: 20130324512
    Abstract: The present invention relates to compounds which are effective as catalysts for dismutating superoxide and, more particularly, the manganese or iron complexes of substituted, unsaturated heterocyclic 16-membered macrocyclic complexes that catalytically dismutate superoxide. It also relates to methods of using these complexes to reduce the concentration or the effects of superoxide, pharmaceutical compositions comprising these compounds or their metal complexes, and methods of treating conditions associated with excessive superoxide activity.
    Type: Application
    Filed: June 12, 2013
    Publication date: December 5, 2013
    Inventor: Dennis P. Riley
  • Patent number: 8598086
    Abstract: 3-Halo-6-(aryl)-4-iminotetrahydropicolinic acids having mono-, di- tri- and tetra-substituted aryl substituents in the 6-position, and their acid derivatives, are herbicides demonstrating a broad spectrum of weed control.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: December 3, 2013
    Assignee: Dow AgroSciences, LLC.
    Inventors: James M. Renga, Paul R. Schmitzer, Gregory T. Whiteker, Kim E. Arndt, Noormohamed M. Niyaz, Christian T. Lowe
  • Patent number: 8597904
    Abstract: The invention disclosed herein generally relates to methods and compositions for inhibiting proteasome activity comprising a syrbactin compound have the structure of Formula (I) or (II).
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: December 3, 2013
    Assignee: Pono Corporation
    Inventors: Andre S. Bachmann, Robert Dudler, Michael Groll
  • Patent number: 8598215
    Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: December 3, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventor: Francis Y. F. Lee
  • Patent number: 8598152
    Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses in pharmaceutical formulations for the treatment of pain.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: December 3, 2013
    Assignee: Laboratorios Del Dr. Esteve, S.A.
    Inventors: Carlos Ramon Plata Salaman, Nicolas Tesson
  • Patent number: 8598216
    Abstract: The invention relates to ritonavir bis-hydrochloride, processes for the preparation of the ritonavir bis-hydrochloride, pharmaceutical compositions containing the ritonavir bis-hydrochloride and made from it, and methods of using the ritonavir bis-hydrochloride to inhibit HIV protease or enhance the pharmacokinetics of compounds which are metabolized by cytochrome P450 3A4.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: December 3, 2013
    Assignee: Abbvie Inc.
    Inventors: Maurizio Acquasaliente, Didier Houllemare, Geoff Zhang, Pulla Singam, John Morris, Kennan Marsh, Martin Babcock, John Pavlina, Yi Shi, Yuchuan Gong
  • Patent number: 8598151
    Abstract: The present invention relates to solid solution inducing layer for the preparation of weak epitaxial films of non-planar phthalocyanine and the thin film of non-planar phthalocyanine generated from the weak epitaxial growth on the solid solution inducing layer and organic thin film transistor based on the weak rpitaxy growth thin film of non-planar phthalocyanine. The solid solution inducing layer is prepared at certain substrate temperature by vapor co-deposition of any two inducing layer molecules presented by Formula I and Formula II. The solid solution inducing layer has uniformed structure, of which the lattice parameter and electronic structure can be controlled by adjusting the component proportion, the solid solution inducing layer can epitaxially grow a high quality thin film of non-planar phthalocyanine and fabricate high performance transistor device based on such epitaxial thin film.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: December 3, 2013
    Assignee: Shanghai Casail Display Technology Ltd.
    Inventors: Donghang Yan, Yanhou Geng, Hongkun Tian, Lizhen Huang, Jianfeng Shen, Xiaodong Guo
  • Patent number: 8598227
    Abstract: This invention relates to a stable epoprostenol composition that can be combined with commercially available IV fluids and can be administered in its reconstituted and/or diluted form under ambient conditions of about 15-30° C. for greater than 24 hours. The composition preferably contains (a) epoprostenol or a salt thereof; (b) a alkalinization agent; and (c) a base, such that when reconstituted or in solution, the solution has a pH>11. Methods for making the lyophilized composition are also disclosed.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: December 3, 2013
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventor: Nagesh R. Palepu
  • Patent number: 8598153
    Abstract: The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, Mycobacterium tuberculosis infections, malarial infections and other apicomplexan protozoal diseases.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: December 3, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sheo B. Singh, Michael R. Tota, Jun Wang
  • Patent number: 8598150
    Abstract: A composition including an effective amount of a compound including manganese [III] tetrakis (4-benzoic acid) porphyrin (MnTBAP), derivatives or analogs thereof to induce a reduction in body weight of a mammal or to improve insulin sensitivity of an obese mammal. A method including introducing an effective amount of a compound including manganese [III] tetrakis (4-benzoic acid) porphyrin (MnTBAP), derivatives or analogs thereof to a mammal to induce a reduction in body weight or to induce an increase in metabolism or insulin sensitivity of the mammal.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: December 3, 2013
    Inventors: Jonathan R. Brestoff, Thomas H. Reynolds, IV
  • Publication number: 20130317043
    Abstract: The invention relates to a compound of Formula I:
    Type: Application
    Filed: May 6, 2013
    Publication date: November 28, 2013
    Applicants: President and Fellows of Harvard College, The Broad Institute, Inc.
    Inventors: The Broad Institute, Inc., President and Fellows of Harvard College
  • Patent number: 8592403
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, L and n are as defined in the specification. These compounds are useful as MC4 agonists.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: November 26, 2013
    Assignee: Pfizer Limited
    Inventors: Mark David Andrews, Christopher Gordon Barber
  • Patent number: 8586570
    Abstract: Peptidyl sensors comprise a metal-binding peptide and one or two kinase recognition sequences with a hydroxyamino acid that can be phosphorylated in the presence of a kinase.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: November 19, 2013
    Assignee: Massachusetts Institute of Technology
    Inventors: Barbara Imperiali, Elvedin Lukovic, Dora Carrico-Moniz
  • Publication number: 20130303461
    Abstract: The technology described herein is directed to methods of determining oligonucleotide sequences, e.g. by enriching target sequences prior to sequencing the sequences.
    Type: Application
    Filed: March 11, 2013
    Publication date: November 14, 2013
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Anthony John Iafrate, Long Phi Le, Zongli Zheng
  • Publication number: 20130302344
    Abstract: The present invention relates to a new method, and the process to manufacture a medicament, for treating gout or pseudogout, comprising administering an effective amount of inhibitors blocking IL-1 or its maturation by the NALP3 inflammasome.
    Type: Application
    Filed: July 16, 2013
    Publication date: November 14, 2013
    Inventors: Virginie Petrilli, Fabio Martinon, Jurg Tschopp, Thibault De Smedt
  • Patent number: 8580777
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: November 12, 2013
    Assignee: Sanofi
    Inventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
  • Patent number: 8580267
    Abstract: Immunocytokine comprising cytokine, e.g. interleukin 2 (IL-2), conjugated to antibody against tumour neovasculature antigen, e.g. tenascin-C, for use in combination therapy with chemotherapeutic agent such as temozolomide. Use of immunocytokine and chemotherapy for treatment of tumours e.g. glioblastoma and other cancers.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: November 12, 2013
    Assignee: Philogen S.p.A.
    Inventors: Marta Pedretti, Dario Neri
  • Patent number: 8580776
    Abstract: This invention provides agents, compositions, pharmaceutical compositions and methods for treating or slowing the progression of a neurodegenerating disease, such as Alzheimer's disease and a demyelinating disease.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: November 12, 2013
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Douglas L. Feinstein, Maria Vittoria Simonini, Sergey Kalinin, Paul E. Polak
  • Patent number: 8580775
    Abstract: The present invention relates to substances which can be used as cosmetic ingredients, especially for skin whitening and as cosmetic agents against signs of ageing skin. The present invention also relates to the use of such substances for the manufacture of a medicament for the treatment of disorders related to the pigmentation of the skin. The invention furthermore relates to specific substances.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: November 12, 2013
    Assignee: Cognis IP Management GmbH
    Inventors: Thomas Markert, Philippe Moussou, Louis Danoux, Andreas Rathjens
  • Patent number: 8575218
    Abstract: Methods and pharmaceutical formulations for ameliorating heavy metal toxicity and/or oxidative stress are disclosed, comprising administering pharmaceutically effective amounts of ligands according to the present disclosure.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: November 5, 2013
    Assignee: The University of Kentucky Research Foundation
    Inventors: Boyd E. Haley, David A. Atwood, Niladri Gupta
  • Patent number: 8574634
    Abstract: Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a formulation of a proanthocyanidin polymer composition which protects the composition from the effects of stomach acid after oral administration, particularly to those formulations which are enteric coated. The invention also relates to methods of producing a directly compressible proanthocyanidin polymer composition, as well as compositions containing the directly compressible proanthocyanidin polymer composition.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: November 5, 2013
    Assignee: Napo Pharmaceutcials, Inc.
    Inventors: Edward James Rozhon, Atul S. Khandwala, Akram Sabouni, Gul P. Balwani, Jody Wai-Han Chan, David F. Sesin
  • Publication number: 20130287698
    Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.
    Type: Application
    Filed: May 16, 2013
    Publication date: October 31, 2013
    Inventor: Kirk Patrick Seward
  • Patent number: 8569278
    Abstract: The present invention provides for a storage stable pharmaceutical liquid solution for oral administration having a pharmaceutically effective amount of an antihistamine and having a purity equal to or greater than about 99% by weight-based HPLC assay, residual solvents of less than about 0.5%, and a total impurity of less than about 0.2%. The storage stable solution preferably contains cetirizine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid solution as well as a method of treating a mammal with a therapeutically effective amount of cetirizine in the stable pharmaceutical liquid solution.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: October 29, 2013
    Assignee: Taro Pharmaceuticals North America, Inc.
    Inventors: Satish Asotra, Jerzy Zadykowicz, Kalpana Vanam, Shen Gao
  • Patent number: 8569325
    Abstract: A method for the prevention of diseases caused by thrombus or embolus. The method is to separately administer 2-acetoxy-5-(?-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, in their pharmacologically effective amounts, to a warm-blooded animal.
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: October 29, 2013
    Assignees: Daiichi Sankyo Company, Limited, Ube Industries, Ltd.
    Inventors: Fumitoshi Asai, Atsuhiro Sugidachi, Taketoshi Ogawa, Teruhiko Inoue
  • Patent number: 8569347
    Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: October 29, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventor: Francis Y. F. Lee
  • Patent number: 8569279
    Abstract: Disclosed is a method for modulating a claudin-mediated function in a mammalian subject which comprises administering to a subject in need thereof an effective amount of a specific fatty acid derivative. The application also discloses a method for treating a dermatological disease and a method for modulating an expression of a claudin in a mammalian subject using the same fatty acid derivative as above.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: October 29, 2013
    Assignees: Sucampo AG, Osaka University
    Inventors: Ryuji Ueno, Sachiko Tsukita
  • Patent number: 8569280
    Abstract: Methods for treating multiple myeloma with inhibitors of CXCR4, such as AMD3100 and anti-CXCR4 antibodies, are described. The decreased expression of CXCR4 on multiple myeloma cells according to the invention results in decreased homing of the cells to the bone marrow and a reduction in the development of the disease. Also disclosed are pharmaceutical compositions incorporating such inhibitors for use in the therapeutic treatment of multiple myeloma. The treatment methods described herein can be used independently, or in conjunction with, other therapies for the treatment of multiple myeloma.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: October 29, 2013
    Assignee: Immune Disease Institute
    Inventors: Ulrich H. von Andrian, Irina Mazo, Jean-Marc Gauguet
  • Publication number: 20130281423
    Abstract: Embodiments of the present invention include methods and compositions for ameliorating cancer. Some embodiments include methods and compositions for ameliorating pancreatic cancer targeting the CXCR4 receptor and the CXCL12 ligand.
    Type: Application
    Filed: October 25, 2011
    Publication date: October 24, 2013
    Applicant: UNIVERSITY OF SOUTH ALABAMA
    Inventors: Seema Singh, Ajay P. Singh
  • Patent number: 8563538
    Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: October 22, 2013
    Assignee: Philera New Zealand Limited
    Inventors: Garth J. S. Cooper, John R. Baker
  • Patent number: 8563779
    Abstract: A description is given of (4-trifluoromethyl-3-thiobenzoyl)cyclohexanediones of the formula (I) and of their use as herbicides. In this formula (I), X, R1, R2, R3, and R4 are radicals such as hydrogen and organic radicals such as alkyl. A and Z are oxygen or alkylene.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: October 22, 2013
    Assignee: Bayer CropScience AG
    Inventors: Hartmut Ahrens, Andreas Van Almsick, Elmar Gatzweiler, Dieter Feucht, Isolde Haeuser-Hahn, Stefan Lehr, Christopher Hugh Rosinger
  • Patent number: 8563537
    Abstract: Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in combination with radiotherapy. New Camptothecin-based compounds are disclosed that are useful for treating cancer by administering the novel compounds alone or in combination with radiotherapy.
    Type: Grant
    Filed: July 29, 2008
    Date of Patent: October 22, 2013
    Assignees: Sutter West Bay Hospital, Catholic Healthcare West
    Inventor: Li-Xi Yang
  • Publication number: 20130273009
    Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula Z-linker-Z???(1) or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 17, 2013
    Inventor: Genzyme Corporation
  • Patent number: 8557799
    Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: October 15, 2013
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 8557804
    Abstract: Nicotine receptor agonists or analogs or derivatives thereof for treating inflammatory pulmonary diseases, and pharmaceutical compositions including nicotine receptor agonists or analogs or derivatives thereof. Compounds of formula wherein R1, R2, Xa and Ya are as defined herein are also provided.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: October 15, 2013
    Assignee: Universite Laval
    Inventors: Yvon Cormier, Evelyne Israel-Assayag, Marie-Renee Blanchet, Rene C. Gaudreault, Philippe Labrie
  • Patent number: 8557803
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 15, 2013
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Patent number: RE44599
    Abstract: Compounds that inhibit P13K? activity, including compounds that selectively inhibit P13K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (P13K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which P13K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: November 12, 2013
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg, Kamal Deep Puri